Rilzabrutinib & First Biosimilar Golimumab Among New EU Filings

 
• By Neena Brizmohun

Sanofi’s rilzabrutinib and Alvotech/Advanz Pharma’s golimumab (AVT05) are among five new entries on the European Medicines Agency’s latest monthly list of products for which marketing applications are currently under review. Both drugs are investigational and are yet to be approved anywhere in the world.

Reduced platelet (thrombocytes) count in Immune thrombocytopenic purpura (ITP) - isometric view 3d
ITP is an autoimmune condition that causes a low platelet count (Shutterstock)

More from EU CHMP

More from Product Reviews